Gianello, Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone, Horm
Choose Injectable Delivery When: Maximum bioavailability and systemic distribution are required Your peptide has a molecular weight exceeding 6,000 Da Precise dosing and reproducible pharmacokinetics are necessary Youre using peptides for bodybuilding or muscle growth The peptide lacks CNS targets Choose Nasal Delivery When: Direct CNS delivery and blood-brain barrier bypass are therapeutic objectives Your peptide is small (under 6,000 Da) and shows adequate nasal bioavailability Rapid onset of action (minutes) is clinically valuable Patient compliance and comfort are primary concerns Youre using neurological peptides like Semax or Selank The FDA has approved several intranasal peptide formulations, including ZAVZPRET for acute migraine treatment, validating this delivery route as pharmaceutically viable
Correct mutations and sequences were confirmed by sequencing both strands
Treating SARS During the SARS outbreak, there were no targeted treatments available
2460055-10-9 Appearance Solid Molecular Weight 5358.06 Formula C 228 H 388 N 86 O 64 Color White to off-white Sequence D-(Leu-Thr-Leu-Arg-Lys-Glu-Pro-Ala-Ser-Glu-Ile-Ala-Gln-Ser-Ile-Leu-Glu-Ala-Tyr-Ser-Gln-Asn-Gly-Trp-Ala-Asn-Arg-Arg-Ser-Gly-Gly-Lys-Arg-Pro-Pro-Pro-Arg-Arg-Arg-Gln-Arg-Arg-Lys-Lys-Arg-Gly) Sequence Shortening D-(LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRPPPRRRQRRKKRG) Shipping Room temperature in continental US
Formulation and Storage Cagrilintide is available as a lyophilized powder